TSX Penny Stocks To Watch In January 2026

As 2026 begins, investors are encouraged to reassess their portfolios with a focus on economic health and diversification, particularly given the recent trends in employment and inflation data. For those interested in smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing investment area when backed by strong financials. This article highlights three penny stocks that showcase financial strength and potential for long-term growth, offering investors the opportunity to uncover hidden value in quality companies.

Top 10 Penny Stocks In Canada

Name	Share Price	Market Cap	Rewards & Risks
Westbridge Renewable Energy (TSXV:WEB)	CA$2.24	CA$55.36M	✅ 3 ⚠️ 4 View Analysis >
Cannara Biotech (TSXV:LOVE)	CA$1.78	CA$173.82M	✅ 3 ⚠️ 0 View Analysis >
Sailfish Royalty (TSXV:FISH)	CA$3.32	CA$251.64M	✅ 1 ⚠️ 4 View Analysis >
Zoomd Technologies (TSXV:ZOMD)	CA$1.30	CA$131.03M	✅ 4 ⚠️ 2 View Analysis >
Montero Mining and Exploration (TSXV:MON)	CA$0.42	CA$3.59M	✅ 2 ⚠️ 3 View Analysis >
CEMATRIX (TSX:CEMX)	CA$0.35	CA$52.48M	✅ 3 ⚠️ 1 View Analysis >
Thor Explorations (TSXV:THX)	CA$1.27	CA$884.85M	✅ 3 ⚠️ 2 View Analysis >
Automotive Finco (TSXV:AFCC.H)	CA$1.19	CA$23.39M	✅ 2 ⚠️ 3 View Analysis >
Pulse Seismic (TSX:PSD)	CA$3.45	CA$173.98M	✅ 2 ⚠️ 1 View Analysis >
Hemisphere Energy (TSXV:HME)	CA$1.97	CA$183.58M	✅ 3 ⚠️ 2 View Analysis >

Click here to see the full list of 380 stocks from our TSX Penny Stocks screener.

Let's explore several standout options from the results in the screener.

Lion Copper and Gold (CNSX:LEO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Lion Copper and Gold Corp. is a mineral exploration company focused on acquiring, exploring, and developing copper projects in the United States with a market cap of CA$97.11 million.

Operations: Lion Copper and Gold Corp. has not reported any revenue segments.

Market Cap: CA$97.11M

Lion Copper and Gold Corp., with a market cap of CA$97.11 million, is a pre-revenue mineral exploration company focused on U.S. copper projects. Recent financial activities include closing a shelf registration for $42.56 million and securing $2.7 million through private placements, indicating efforts to bolster capital amid ongoing net losses—USD 3.6 million in Q3 2025 alone, up from USD 0.034 million the previous year. The company's cash runway is forecasted at seven months but has been extended by recent capital raises, while its short-term liabilities exceed current assets by US$1.3 million, reflecting potential liquidity challenges amidst high share price volatility and unprofitability concerns.

• Click here to discover the nuances of Lion Copper and Gold with our detailed analytical financial health report.
• Gain insights into Lion Copper and Gold's past trends and performance with our report on the company's historical track record.

Anaergia (TSX:ANRG)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Anaergia Inc. offers renewable energy solutions and waste-to-resource conversion services across various regions including Italy, North America, Europe, the Middle East and Africa, and the Asia Pacific, with a market cap of CA$403.99 million.

Operations: The company generates revenue primarily through Capital Sales (CA$108.54 million), followed by O&M Services (CA$20.65 million) and Build, Own, and Operate activities (CA$13.37 million).

Market Cap: CA$403.99M

Anaergia Inc., with a market cap of CA$403.99 million, is navigating challenges typical of penny stocks. Despite being unprofitable and having high net debt to equity ratio (64.1%), the company has a positive cash runway exceeding three years due to growing free cash flow. Recent contracts, including a CA$43.8 million deal in San Diego and an agreement with PepsiCo Mexico Foods, highlight its strategic expansion in renewable energy solutions. However, legal issues persist with class action lawsuits alleging misrepresentation during past share offerings, adding potential risk for investors amidst ongoing financial volatility and insider selling activities.

• Navigate through the intricacies of Anaergia with our comprehensive balance sheet health report here.
• Examine Anaergia's earnings growth report to understand how analysts expect it to perform.

Theralase Technologies (TSXV:TLT)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on the research, development, and commercialization of light activated photodynamic compounds for treating cancers, bacteria, and viruses globally, with a market cap of CA$54.31 million.

Operations: The company's revenue segment includes CA$1 million from its Device business line.

Market Cap: CA$54.31M

Theralase Technologies Inc., with a market cap of CA$54.31 million, remains a speculative investment due to its pre-revenue status, generating less than US$1 million annually. The company recently raised capital through private placements totaling over CA$8.83 million, enhancing its financial runway despite short-term liabilities exceeding assets by CA$0.3 million as of September 2025. The management team is experienced with an average tenure of 15.4 years, providing stability amidst ongoing clinical trials for innovative cancer treatments like Rutherrin®. However, the company's negative return on equity and lack of profitability highlight inherent risks typical in the biotech sector.

• Unlock comprehensive insights into our analysis of Theralase Technologies stock in this financial health report.
• Understand Theralase Technologies' earnings outlook by examining our growth report.

Make It Happen

• Explore the 380 names from our TSX Penny Stocks screener here.
• Interested In Other Possibilities? AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com